In Vitro Coagulation Time Determination: Principles, Methods, and Applications for Blood-Contacting

In vitro coagulation time determination is a core hemocompatibility test used to evaluate whether blood-contacting medical devices and biomaterials activate or inhibit the coagulation system. Performed in accordance with ISO 10993-4 and its Chinese counterpart GB/T 16886.4, the method quantifies changes in activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) after blood or plasma contacts a test material. This article explains the testing principles, sample requirements, methodology, result interpretation, and typical applications in regulatory submission and product development.

Technical Overview

In vitro coagulation time determination is a laboratory-based hemocompatibility assay that measures the effect of a medical device or biomaterial on the time required for blood or plasma to form a clot. When blood contacts a foreign surface, adsorbed plasma proteins can activate factor XII and the intrinsic coagulation cascade, or trigger the extrinsic pathway through tissue factor expression, leading to thrombin generation and fibrin clot formation. A material that accelerates clotting poses a thrombogenic risk, while a material that prolongs clotting may release substances with anticoagulant activity, which can also be clinically undesirable.

The test is one of the five hemocompatibility categories defined in ISO 10993-4 and GB/T 16886.4 (thrombosis, coagulation, platelets, hematology, and complement system). For devices with limited or circulating blood contact, such as catheters, cannulae, hemodialyzers, oxygenators, vascular grafts, and infusion sets, coagulation testing is generally expected as part of the biological evaluation. Because the assay is conducted entirely outside the body using citrated human or animal blood, it provides a controlled, reproducible, and ethically preferable alternative to in vivo thrombogenicity studies for early-stage screening and batch release testing.

Modern implementations rely on automated coagulation analyzers that detect clot formation optically or mechanically, following the same analytical principles used in clinical coagulation laboratories for APTT, PT, and TT measurements. Results are compared against negative and positive controls, and statistical analysis is applied to determine whether the test material significantly alters coagulation kinetics.

Testing Samples

Blood-Contacting Medical Devices

Finished devices or representative sections of devices that are intended to contact circulating blood or blood in an extracorporeal circuit are the primary test articles. Typical examples include:

• Intravascular catheters, guidewires, introducer sheaths, and cannulae
• Hemodialyzers, hemoperfusion cartridges, and extracorporeal circuit tubing sets
• Membrane oxygenators and cardiopulmonary bypass components
• Vascular grafts, stents, stent grafts, and heart valve components
• Blood collection bags, transfusion sets, and infusion devices
• Pumps, sensors, and other blood-contacting hardware

Biomaterials, Surface Coatings, and Candidate Materials

During research and development, flat films, molded plaques, tubing segments, or coated coupons of candidate materials can be tested to compare thrombogenic potential. Antithrombotic or hydrophilic coatings applied to device surfaces are frequently evaluated to demonstrate that they prolong coagulation time relative to an uncoated substrate, which serves as evidence of functional performance.

Sample Preparation Requirements

Test samples should represent the final product in its sterilized, clinically relevant condition. Key preparation considerations include:

• Samples must be sterilized by the intended production method, since sterilization can alter surface chemistry and thrombogenicity.
• A defined surface-area-to-fluid ratio (commonly 3 cm²/mL to 6 cm²/mL for polymeric materials, consistent with ISO 10993-12 extraction principles) must be documented and justified.
• Test surfaces should be clean, free of processing residues, and cut or handled in a way that does not introduce contamination or rough edges that could activate clotting artificially.
• Both direct-contact configurations (material incubated with blood or plasma) and indirect configurations (material extract incubated with blood or plasma) may be used, depending on the intended clinical exposure and the device geometry.

Testing Items

Depending on the study design and the intended use of the device, one or more of the following coagulation parameters are measured:

• Activated Partial Thromboplastin Time (APTT): Assesses the intrinsic and common coagulation pathways (factors VIII, IX, XI, XII, and downstream factors). Shortening of APTT after material contact indicates activation of the intrinsic pathway, which is the most common signature of a thrombogenic surface.
• Prothrombin Time (PT): Assesses the extrinsic and common pathways, primarily tissue factor and factor VII activity. PT is particularly relevant for devices that may release tissue-factor-bearing particles or leukocyte-activating leachables.
• Thrombin Time (TT): Measures the conversion of fibrinogen to fibrin by added thrombin. TT is sensitive to heparin-like leachables, fibrin degradation products, and abnormal fibrinogen function.
• Recalcification Time (Plasma Clotting Time): A simpler whole-plasma assay in which calcium chloride is added to citrated plasma after material contact and the time to visible clot formation is recorded.
• Supplementary Markers: Some study designs add fibrinogen concentration, thrombin-antithrombin complex (TAT), or thrombin generation assays (TGA) to provide deeper mechanistic insight into coagulation activation.

Testing Methods

Test Principle and General Procedure

The general workflow follows the framework of ISO 10993-4 and GB/T 16886.4 combined with standard clinical coagulation methodology:

• Blood is collected from consenting healthy human donors (or defined animal donors where justified) into 3.2% sodium citrate anticoagulant at a 9:1 blood-to-anticoagulant ratio.
• Platelet-poor or platelet-rich plasma is prepared by centrifugation, or citrated whole blood is used directly for certain protocols.
• The test sample, negative control, and positive control are incubated with the blood or plasma at 37 °C for a defined contact time (typically 15 to 60 minutes, or longer for extracorporeal applications).
• After the contact period, the plasma is transferred to a coagulation analyzer and the appropriate reagent system is added: APTT reagent plus calcium chloride for APTT, thromboplastin with calcium for PT, or standardized thrombin for TT.
• The time from reagent addition to clot detection is recorded automatically by optical or mechanical endpoints.
• Each condition is tested in replicate, and data from multiple donors (commonly at least three) are pooled or analyzed separately to address biological variability.

Direct Contact versus Indirect (Extract) Approach

In the direct contact method, the material physically contacts blood or plasma during the incubation step, which best reflects the clinical situation for surface-contacting devices. In the indirect method, a material extract prepared under controlled conditions is mixed with blood or plasma, which evaluates the effect of soluble leachables. The choice between the two approaches should be based on the device's intended blood-contact duration and geometry, and both are accepted by ISO 10993-4 when scientifically justified.

Controls and Reference Materials

Each assay run must include appropriate controls to validate test sensitivity:

• Negative control: A non-thrombogenic reference material such as medical-grade polyethylene, or plasma incubated without any material (blank control).
• Positive control: A surface known to activate the intrinsic pathway, such as glass, which should demonstrably shorten APTT; heparin may serve as a positive control for prolongation in TT assays.
• Reagent and instrument controls: Normal and abnormal reference plasmas are used to confirm analyzer performance and reagent integrity.

Result Interpretation

Coagulation times of the test group are compared with the negative control group using appropriate statistical methods, typically a t-test or analysis of variance with a significance level of 0.05. Interpretation follows the general conventions below:

• Significantly shortened coagulation time: Indicates procoagulant or thrombogenic activity of the material or its leachables, warranting surface modification or further risk assessment.
• No significant difference: The material is considered non-activating with respect to coagulation under the tested conditions.
• Significantly prolonged coagulation time: Suggests release of anticoagulant substances (for example, heparin-based coatings or leachable additives). For antithrombotic-coated devices this may be the intended effect and can be presented as evidence of coating functionality.

Many protocols apply a practical decision threshold, for example a change greater than 10–15% relative to the negative control, in addition to statistical significance. Results should always be interpreted together with other hemocompatibility endpoints such as hemolysis (ASTM F756, GB/T 16886.4), platelet activation, and complement activation.

Applications

In vitro coagulation time determination supports the medical device lifecycle from material selection through market approval:

• Regulatory submission: Hemocompatibility data packages for registration with authorities such as NMPA, FDA, and EU notified bodies under the EU MDR routinely include APTT, PT, and TT results referenced to ISO 10993-4 and GB/T 16886.4. Accredited third-party laboratories commonly perform these studies to satisfy documentation requirements.
• Material and coating development: Screening candidate polymers, metals, and surface treatments during design to select low-thrombogenicity options before costly in vivo studies.
• Antithrombotic coating verification: Demonstrating that heparin-coated or other passivated surfaces extend coagulation time compared with uncoated controls.
• Change control and batch release: Confirming that changes in supplier, processing, sterilization, or coating lot do not degrade hemocompatible performance.
• Scientific research: Investigating blood–material interactions, protein adsorption effects, and novel blood-contacting biomaterials in academic and industrial laboratories.

FAQ

What standards govern in vitro coagulation time testing?

The primary standard is ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), which is adopted in China as GB/T 16886.4. Sample preparation ratios follow ISO 10993-12 / GB/T 16886.12, and hemolysis testing that often accompanies coagulation studies follows ASTM F756 and related clauses of GB/T 16886.4. The analytical measurement of APTT, PT, and TT follows established clinical coagulation methodology.

What blood source is used for the test?

Healthy human donor blood collected in 3.2% sodium citrate is preferred because it best represents clinical exposure. ISO 10993-4 permits pooled plasma for coagulation assays, while platelet and complement assays require individual donors. Animal blood, most commonly rabbit or ovine blood, may be used with scientific justification, but human blood is generally recommended for coagulation endpoints.

How long does a typical study take?

The laboratory phase, including donor blood collection, incubation, and coagulation analysis, is usually completed within one day because coagulation factors degrade rapidly after collection. Including sample preparation, control runs, data analysis, and reporting, a complete study is typically delivered within two to four weeks.

What does a shortened coagulation time mean for my device?

A significant shortening of APTT relative to the negative control indicates that the material or its leachables activate the coagulation cascade, most commonly the contact (intrinsic) pathway. This finding should trigger a risk assessment, which may lead to surface passivation, coating application, extraction refinement, or complementary in vivo thrombogenicity testing.

Can a prolonged coagulation time ever be a good result?

Yes. For devices deliberately engineered with anticoagulant surfaces, such as heparin-bonded circuits or coated catheters, a significantly prolonged APTT or TT versus the uncoated substrate demonstrates that the coating is leaching or expressing active anticoagulant function, which is often a claimed performance benefit.

How does in vitro coagulation testing differ from in vivo thrombogenicity testing?

In vitro tests are faster, cheaper, and free of animal use, and they isolate the coagulation endpoint under controlled conditions. However, they cannot reproduce the shear stress, endothelial interaction, and flow dynamics of living circulation. ISO 10993-4 categorizes blood-contacting devices by contact nature and duration and uses a risk-based rationale to determine whether in vitro data alone are sufficient or whether in vivo studies are also required.

What should be included in the final test report?

A compliant report includes device and material description, sterilization status, sample preparation and surface-area-to-volume ratio, blood donor information and anticoagulant details, contact conditions, controls used, APTT/PT/TT results with replicate data, statistical comparison against controls, identification of the positive control effect, deviation records, and a conclusion stating whether the test material alters coagulation time under the tested conditions.